TBFA
NVCR icon

Three Bearings Fiduciary Advisors’s NovoCure NVCR Stock Holding History

Three Bearings Fiduciary Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.54K Hold
300
– – ﹤0.01% 168
2026
Q1 		$3.27K Hold
300
– – ﹤0.01% 178
2025
Q4 		$3.72K Buy
+300
New +$3.85K ﹤0.01% 183

Other funds holding NVCR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
BC
Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return

Three Bearings Fiduciary Advisors's NVCR Position: Q2 2026 in Review

Three Bearings Fiduciary Advisors held its NovoCure (NVCR) position steady in Q2 2026 at 300 shares worth $4.54K. The position accounts for ﹤0.01% of the portfolio, ranked #168.

Three Bearings Fiduciary Advisors first reported a position in NVCR in Q4 2025 and has held it in 3 quarters since. 76 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Three Bearings Fiduciary Advisors held 300 shares of NovoCure worth $4.54K as of Q2 2026.
  • Three Bearings Fiduciary Advisors left its NovoCure share count unchanged in Q2 2026.
  • NovoCure made up ﹤0.01% of Three Bearings Fiduciary Advisors's portfolio in Q2 2026, its #168 holding.
  • Three Bearings Fiduciary Advisors first reported a position in NovoCure in Q4 2025 and has held it in 3 quarters since.
  • 76 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Three Bearings Fiduciary Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.